- Home
- BCLI vs IGC Comparison
BCLI vs IGC Comparison
Compare BCLI & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- IGC
- Stock Information
- Founded
- BCLI 2000
- IGC 2005
- Country
- BCLI United States
- IGC United States
- Employees
- BCLI N/A
- IGC N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- IGC Health Care
- Exchange
- BCLI Nasdaq
- IGC Nasdaq
- Market Cap
- BCLI 25.0M
- IGC 23.8M
- IPO Year
- BCLI N/A
- IGC N/A
- Fundamental
- Price
- BCLI $2.19
- IGC $0.40
- Analyst Decision
- BCLI Strong Buy
- IGC Strong Buy
- Analyst Count
- BCLI 1
- IGC 2
- Target Price
- BCLI $30.00
- IGC $3.63
- AVG Volume (30 Days)
- BCLI 83.7K
- IGC 713.9K
- Earning Date
- BCLI 11-12-2024
- IGC 11-11-2024
- Dividend Yield
- BCLI N/A
- IGC N/A
- EPS Growth
- BCLI N/A
- IGC N/A
- EPS
- BCLI N/A
- IGC N/A
- Revenue
- BCLI N/A
- IGC $1,062,000.00
- Revenue This Year
- BCLI N/A
- IGC N/A
- Revenue Next Year
- BCLI N/A
- IGC $13.57
- P/E Ratio
- BCLI N/A
- IGC N/A
- Revenue Growth
- BCLI N/A
- IGC N/A
- 52 Week Low
- BCLI $1.95
- IGC $0.25
- 52 Week High
- BCLI $11.85
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- BCLI 32.84
- IGC 57.09
- Support Level
- BCLI $1.97
- IGC $0.35
- Resistance Level
- BCLI $2.68
- IGC $0.41
- Average True Range (ATR)
- BCLI 0.33
- IGC 0.02
- MACD
- BCLI 0.05
- IGC 0.00
- Stochastic Oscillator
- BCLI 16.91
- IGC 74.00
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.